Skip to main content
Top
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells

Authors: Huiyu Zhuang, Mingzi Tan, Juanjuan Liu, Zhenhua Hu, Dawo Liu, Jian Gao, Liancheng Zhu, Bei Lin

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

The objective of the present study was to identify human epididymis protein 4 (HE4) interacting proteins and explore the mechanisms underlying their effect on ovarian cancer cell invasion and metastasis.

Methods

HE4 interacting proteins were identified by mass spectrometry and validated by co-immunoprecipitation and pull-down assays. The scratch test, the Transwell assay and animal experiments were used to assess the invasive and metastatic abilities of ovarian cancer cells before and after transfection and HE4 protein treatment. HE4 and annexin II protein expression in epithelial ovarian tissues was detected by immunohistochemistry, and the relation between their expression levels was examined.

Results

Annexin II was identified as an HE4 interacting protein. HE4 and annexin II binding interaction promoted ovarian cancer cell invasion and metastasis. HE4 and annexin II expression levels were significantly higher in malignant epithelial ovarian tissues than in benign and normal epithelial ovarian tissues, and they were higher in tissues with lymph node metastases than in those without. HE4 gene interference downregulated the expression of MAPK and the FOCAL adhesion signaling pathway-associated molecules MKNK2 and LAMB2, and HE4 protein supplementation reversed this effect.

Conclusion

The binding interaction between HE4 and annexin II activates the MAPK and FOCAL adhesion signaling pathways, promoting ovarian cancer cell invasion and metastasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010CrossRefPubMed
2.
go back to reference BW S: KP: WHO World Cancer Report. 2003, Lyon (France): IARC Press, BW S: KP: WHO World Cancer Report. 2003, Lyon (France): IARC Press,
3.
go back to reference Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L: Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999, 238: 375-385. 10.1016/S0378-1119(99)00342-XCrossRefPubMed Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L: Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999, 238: 375-385. 10.1016/S0378-1119(99)00342-XCrossRefPubMed
4.
go back to reference Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63: 3695-3700.PubMed Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63: 3695-3700.PubMed
5.
go back to reference Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J: Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene. 1999, 229: 101-108. 10.1016/S0378-1119(99)00035-9CrossRefPubMed Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J: Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene. 1999, 229: 101-108. 10.1016/S0378-1119(99)00035-9CrossRefPubMed
6.
go back to reference Yu S, Yang HJ, Xie SQ, Bao YX: Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012, 50: 1439-1446.CrossRefPubMed Yu S, Yang HJ, Xie SQ, Bao YX: Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012, 50: 1439-1446.CrossRefPubMed
7.
go back to reference Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65: 2162-2169. 10.1158/0008-5472.CAN-04-3924CrossRefPubMed Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65: 2162-2169. 10.1158/0008-5472.CAN-04-3924CrossRefPubMed
8.
go back to reference Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L: Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012, 419: 274-280. 10.1016/j.bbrc.2012.02.008CrossRefPubMed Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L: Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012, 419: 274-280. 10.1016/j.bbrc.2012.02.008CrossRefPubMed
9.
go back to reference Zhu YF, Gao GL, Tang SB, Zhang ZD, Huang QS: Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro. Asian Pac J Trop Med. 2013, 6: 265-272. 10.1016/S1995-7645(13)60055-3CrossRefPubMed Zhu YF, Gao GL, Tang SB, Zhang ZD, Huang QS: Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro. Asian Pac J Trop Med. 2013, 6: 265-272. 10.1016/S1995-7645(13)60055-3CrossRefPubMed
10.
go back to reference Chasserot-Golaz S, Vitale N, Umbrecht-Jenck E, Knight D, Gerke V, Bader MF: Annexin 2 promotes the formation of lipid microdomains required for calcium-regulated exocytosis of dense-core vesicles. Mol Biol Cell. 2005, 16: 1108-1119. 10.1091/mbc.E04-07-0627PubMedCentralCrossRefPubMed Chasserot-Golaz S, Vitale N, Umbrecht-Jenck E, Knight D, Gerke V, Bader MF: Annexin 2 promotes the formation of lipid microdomains required for calcium-regulated exocytosis of dense-core vesicles. Mol Biol Cell. 2005, 16: 1108-1119. 10.1091/mbc.E04-07-0627PubMedCentralCrossRefPubMed
11.
go back to reference Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V: Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem. 2005, 280: 20833-20841. 10.1074/jbc.M412653200CrossRefPubMed Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V: Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem. 2005, 280: 20833-20841. 10.1074/jbc.M412653200CrossRefPubMed
12.
go back to reference Tanaka T, Akatsuka S, Ozeki M, Shirase T, Hiai H, Toyokuni S: Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis. Oncogene. 2004, 23: 3980-3989. 10.1038/sj.onc.1207555CrossRefPubMed Tanaka T, Akatsuka S, Ozeki M, Shirase T, Hiai H, Toyokuni S: Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis. Oncogene. 2004, 23: 3980-3989. 10.1038/sj.onc.1207555CrossRefPubMed
13.
go back to reference Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O, Maelandsmo GM: S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 1999, 59: 4702-4708.PubMed Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O, Maelandsmo GM: S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 1999, 59: 4702-4708.PubMed
14.
go back to reference Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO: S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 2003, 20: 701-711.CrossRefPubMed Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO: S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 2003, 20: 701-711.CrossRefPubMed
15.
go back to reference Ortiz-Zapater E, Peiro S, Roda O, Corominas JM, Aguilar S, Ampurdanes C, Real FX, Navarro P: Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol. 2007, 170: 1573-1584. 10.2353/ajpath.2007.060850PubMedCentralCrossRefPubMed Ortiz-Zapater E, Peiro S, Roda O, Corominas JM, Aguilar S, Ampurdanes C, Real FX, Navarro P: Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol. 2007, 170: 1573-1584. 10.2353/ajpath.2007.060850PubMedCentralCrossRefPubMed
16.
go back to reference Delys L, Detours V, Franc B, Thomas G, Bogdanova T, Tronko M, Libert F, Dumont JE, Maenhaut C: Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene. 2007, 26: 7894-7903. 10.1038/sj.onc.1210588CrossRefPubMed Delys L, Detours V, Franc B, Thomas G, Bogdanova T, Tronko M, Libert F, Dumont JE, Maenhaut C: Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene. 2007, 26: 7894-7903. 10.1038/sj.onc.1210588CrossRefPubMed
17.
go back to reference Zhang Y, Zhou ZH, Bugge TH, Wahl LM: Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin. J Immunol. 2007, 179: 3297-3304. 10.4049/jimmunol.179.5.3297CrossRefPubMed Zhang Y, Zhou ZH, Bugge TH, Wahl LM: Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin. J Immunol. 2007, 179: 3297-3304. 10.4049/jimmunol.179.5.3297CrossRefPubMed
18.
go back to reference Sabbatini PJ, Ragupathi G, Hood CAC, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu RN, Dansihefsky SJ, Livingston PO: Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res. 2007, 14: 2631-2638. Sabbatini PJ, Ragupathi G, Hood CAC, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu RN, Dansihefsky SJ, Livingston PO: Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res. 2007, 14: 2631-2638.
19.
go back to reference LeBleu VS, Teng Y, O'Connell JT, Charytan D, Muller GA, Muller CA, Sugimoto H, Kalluri R: Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013, 19: 227-231. 10.1038/nm.2989PubMedCentralCrossRefPubMed LeBleu VS, Teng Y, O'Connell JT, Charytan D, Muller GA, Muller CA, Sugimoto H, Kalluri R: Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013, 19: 227-231. 10.1038/nm.2989PubMedCentralCrossRefPubMed
20.
go back to reference Zhuang H, Gao J, Hu Z, Liu J, Liu D, Lin B: Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 2013, 8: e68994- 10.1371/journal.pone.0068994PubMedCentralCrossRefPubMed Zhuang H, Gao J, Hu Z, Liu J, Liu D, Lin B: Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 2013, 8: e68994- 10.1371/journal.pone.0068994PubMedCentralCrossRefPubMed
21.
go back to reference Zhuang H, Hu Z, Tan M, Zhu L, Liu J, Liu D, Yan L, Lin B: Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells. Biochimie. 2014, 105: 91-98.CrossRefPubMed Zhuang H, Hu Z, Tan M, Zhu L, Liu J, Liu D, Yan L, Lin B: Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells. Biochimie. 2014, 105: 91-98.CrossRefPubMed
22.
go back to reference Gallagher SJ, Luciani F, Berlin I, Rambow F, Gros G, Champeval D, Delmas V, Larue L: General strategy to analyse melanoma in mice. Pigment Cell Melanoma Res. 2011, 24: 987-988. 10.1111/j.1755-148X.2011.00907.xCrossRefPubMed Gallagher SJ, Luciani F, Berlin I, Rambow F, Gros G, Champeval D, Delmas V, Larue L: General strategy to analyse melanoma in mice. Pigment Cell Melanoma Res. 2011, 24: 987-988. 10.1111/j.1755-148X.2011.00907.xCrossRefPubMed
Metadata
Title
Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells
Authors
Huiyu Zhuang
Mingzi Tan
Juanjuan Liu
Zhenhua Hu
Dawo Liu
Jian Gao
Liancheng Zhu
Bei Lin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-243

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine